Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [911]

PD-1–refractory advanced melanoma: how do we get to the finish line?

Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA

$PD-1–refractory advanced melanoma: how do we get to the finish line? ( Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA )$

Highlights in melanoma from ASCO 2024

Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA

Highlights in melanoma from ASCO 2024 ( Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA )

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients...

Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy ( Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy )

ASCO 2024: Lung cancer roundup

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

ASCO 2024: Lung cancer roundup ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Trial argues strongly for the development of 1st-line biomarker selected...

Prof Jennifer Knox - University of Toronto, Toronto, Canada

Trial argues strongly for the development of 1st-line biomarker selected strategies in pancreatic ductal adenocarcinoma ( Prof Jennifer Knox - University of Toronto, Toronto, Canada )

ASCO 2024: Latest in mRCC treatment

Dr Sumanta Kumar Pal, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Thomas...

ASCO 2024: Latest in mRCC treatment ( Dr Sumanta Kumar Pal, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Thomas Powles )

Durvalumab after chemoradiotherapy improves survival in limited-stage SCLC

Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA

Durvalumab after chemoradiotherapy improves survival in limited-stage SCLC ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )

Chemotherapy before and after surgery may be new standard treatment for some...

Prof Jens Hoeppner - University of Bielefeld, Bielefeld, Germany

Chemotherapy before and after surgery may be new standard treatment for some patients with oesophageal cancer ( Prof Jens Hoeppner - University of Bielefeld, Bielefeld, Germany )

Immune therapy with belantamab mafodotin and elotuzumab shows encouraging...

Dr Natalia Neparidze - Yale School of Medicine, New Haven, USA

Osimertinib success in locally advanced EGFR-mutated NSCLC

Dr Suresh Ramalingam - Emory University School of Medicine, Atlanta, USA

Osimertinib success in locally advanced EGFR-mutated NSCLC ( Dr Suresh Ramalingam - Emory University School of Medicine, Atlanta, USA )

Adjuvant avelumab versus control does not significantly improve DFS but does...

Prof Pier Conte - University of Padova, Padova, Italy

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients ( Prof Pier Conte - University of Padova, Padova, Italy )

Adagrasib improves on docetaxel in previously treated NSCLC

Dr Robert Jotte - Rocky Mountain Cancer Centers, Colorado

Adagrasib improves on docetaxel in previously treated NSCLC ( Dr Robert Jotte - Rocky Mountain Cancer Centers, Colorado )

More from ecancer